H927 Doxapram HCl - AK Scientific
 
 
Loading Please Wait...
  Catalog ID # H927
Doxapram HCl
, 98%
 
3,3-Diphenyl-1-ethyl-4-(2-morpholinoethyl)-2-pyrrolidinone hydrochloride




IDENTITY
CAS Registry #:[7081-53-0]
MDL Number:MFCD00072148
MF:C24H30N2O2.HCl
MW:414.9681
SPECIFICATIONS & PROPERTIES
Purity:98%
Physical Form:White powder
Melting Point:217-219°C
Shipping:Normal Temperature

BIOLOGICAL INFO
Application(s):Central Nervous System Stimulant; Respiratory System Agent
Form:HCl salt

REVIEW

 Doxapram HCl is an analeptic agent (a stimulant of the central nervous system), a central respiratory stimulant with a brief duration of action. It produces respiratory stimulation mediated through the peripheral carotid chemoreceptors. Therefore, it is used in intensive care settings to stimulate the respiratory rate in patients with respiratory failure.

REFERENCES
[1]Boutroy, Marie-Jeanne. Pharmacology and use of methylxanthines and doxapram for the treatment of neonatal apnea. Edited by Jacqz-Aigrain; Choonara, Imti. Paediatric Clinical Pharmacology. (2006) 417-423.
[2] Yost CS. A new look at the respiratory stimulant doxapram. CNS Drug Rev. (2006) Fall-Winter;12(3-4): 236-49.
[3] Bhatia J. Current options in the management of apnea of prematurity. Clinical pediatrics. (2000) 39(6): 327-36.
[4] Lunsford, Carl D.; Cale, Albert D., Jr.4-(omega-Substituted alkyl)-3,3-disubstituted-1-substituted-2-pyrrolidinones and 4-(omega-substituted alkyl)-3,3-disubstituted-1-substituted-2-pyrrolidinethiones (1965), US 3192221 19650629
[5] Lunsford, Carl D.; Cale, Albert D., Jr. 4-(omega-Substituted alkyl)-3,3-disubstituted- 1-substituted-2-pyr rolidinones and 4-(omega-substituted alkyl)-3,3-disubstituted-2-pyrrolidinethiones (1965), US 3192210 19650629.
[6] Lunsford, Carl D.; Cale, Albert D., Jr.1,3,3-Trisubstituted-4-(beta-haloalkyl)-2-pyrrolidinone (1965), US 3192230 19650629.
[7] Lunder, Hans G.Doxapram, new analeptic agent Norsk Veterinaertidsskrift (1973), 85(12), 635-9
[8] Henderson-Smart D J; Davis P G Prophylactic doxapram for the prevention of morbidity and mortality in preterm infants undergoing endotracheal extubation The Cochrane database of systematic reviews (2000), (3), CD001966
[9] Henderson-Smart D J; Steer P Doxapram versus methylxanthine for apnea in preterm infants The Cochrane database of systematic reviews (2000), (2), CD000075.
[10] Henderson-Smart D J; Steer P Doxapram versus methylxanthine for apnea in preterm infants The Cochrane database of systematic reviews (2000), (4), CD000075.
[11] Henderson-Smart D J; Steer P A Doxapram treatment for apnea in preterm infants The Cochrane database of systematic reviews (2000), (2), CD000074.
[12] Greenstone M Doxapram for ventilatory failure due to exacerbations of chronic obstructive pulmonary disease The Cochrane database of systematic reviews (2000), (2), CD000223.
[13] Henderson-Smart D J; Steer P A Doxapram treatment for apnea in preterm infants The Cochrane database of systematic reviews (2001), (4), CD000074.
[14] Greenstone M; Lasserson T J Doxapram for ventilatory failure due to exacerbations of chronic obstructive pulmonary disease The Cochrane database of systematic reviews (2003), (1), CD000223.
[15] Henderson-Smart D; Steer P Doxapram treatment for apnea in preterm infants The Cochrane database of systematic reviews (2004), (4), CD000074

Risk Description(s)
R36/37/38:Irritating to eyes, respiratory system and skin

Safety Description(s)
S24/25:Avoid contact with skin and eyes.


Pricing (not showing? please refresh your web browser)

CATEGORIES

 APIs and Bioactives

USEFUL LINKS

  PubChem